Home high-flow therapy after AECOPD: results of the UK feasibility study

Can HFT improve clinical, patient-reported and physiological outcomes in patients recovering from severe COPD exacerbation? Dr D’Cruz presents the results of a recent feasibility study.
This is a secured video. To access it for the first time you must fill-in your email address above.

Key facts

  • ERS CONGRESS 2022
  • WITH DR REBECCA D'CRUZ
  • CLINICAL ADOPTION IN HIGH-FLOW THERAPY

Content

Exacerbations manifest to patients as increased burdens of breathlessness, cough, and thick, tenacious sputum that can be difficult to clear. They are distressing for patients, may result in hospitalisation, and tend to become more frequent as COPD progresses.

To explore whether HFT is able to improve clinical, patient-reported and physiological outcomes in COPD patients recovering from severe exacerbations, Dr D’Cruz performed a mixed method, feasibility, randomised control trial in a group of home-based patients from 40 to 80 years old who had a smoking history of more than 10 packs per year, a BMI of less than 35, and no need for acute NIV or established respiratory support at home. The study cohort had an annual exacerbation frequency of four.

As Dr D’Cruz explains, the study revealed how patients choose to interact with HFT when they are given relatively free rein to set their usage levels. It also provided useful qualitative insights into device acceptability and usability, the opportunity cost and coherence of HFT therapy for patients, and its perceived effectiveness, particularly with regard to sputum production and clearance. A multicentre randomised controlled trial is now in the pipeline.

Register to watch the webinar to hear Dr D’Cruz explain the study protocol and discuss her findings.

Speakers

Dr Rebecca D'Cruz

Royal Free London NHS Foundation Trust, UK

Looking for more information about high-flow treatment for COPD patients?

Research in home high-flow therapy for COPD

Discover key findings from recent clinical research on the mechanisms of action of home high-flow therapy and the clinical outcomes in patients with COPD.
Learn more

The HiFAE trial

Read more about the new French randomised controlled trial: HiFAE. The main objective of this study is to evaluate the efficacy of home high-flow therapy with oxygen vs standard oxygen therapy for the reduction of acute COPD exacerbations.
Learn more

Home high-flow therapy for COPD

Learn how home high flow therapy could be indicated for domiciliary use in COPD patients experiencing secretion management issues.
Learn more